Innovative Health: The Rival That Won in CourtNarrow moat
Johnson & Johnson (JNJ) — moat facet
A company that reprocesses J&J's used heart catheters won an antitrust verdict and an injunction against J&J's best device business.
The oddest competitor on J&J's list is a company that resells used versions of J&J's own products. In October 2019 Innovative Health, a medical device reprocessing company1, sued J&J's Biosense Webster, alleging that certain business practices and contractual terms violated the antitrust laws by restricting competition in the sale of high density mapping catheters and ultrasound catheters2. In May 2025 a jury returned its verdict in favour of Innovative Health, and in August 2025 the court issued a permanent injunction concerning Biosense Webster's business practices3. Biosense Webster appealed both4.
The case goes to the heart of how device moats work. Electrophysiology is the largest part of J&J's cardiovascular franchise, with $5,634 million of sales in 20255, and part of its strength is the link between the mapping system a hospital owns and the catheters it buys. When that link is enforced by contract, a court can loosen it.
A reprocessor competes on cost. Innovative Health's own case to hospitals is that electrophysiology economics are all about the cost per procedure of medical devices, and that some individual catheters cost more than $4,0006. Every catheter reused after reprocessing is a new catheter J&J does not sell.
The injunction's effect is not yet visible in the aggregate numbers. United States electrophysiology grew 5.8% in the second quarter of 2026 to $783 million7. The filing records the verdict but not the damages amount.
J&J faces similar claims elsewhere. Actelion, a J&J subsidiary, faces a class action alleging it violated antitrust laws by refusing to supply generic manufacturers with samples of Tracleer, a pulmonary hypertension drug8. In both cases the accusation is that J&J used contract or distribution control to keep cheaper rivals out, which is exactly what a moat looks like from the other side.
The rival itself is small, but what it established is not: the courts can limit J&J's use of contract terms to protect its installed base. United States electrophysiology growth is where it would show; a fall below 3% while procedures grow would suggest hospitals are buying more reprocessed catheters.
The injunction limits contract practices that protected the catheter business; J&J is appealing.
Where reprocessed catheters would show up; growth below 3% while procedures grow would suggest share lost to reprocessors.
Source: Johnson & Johnson Q2 2026 financial schedules ↗- ReportedIn October 2019 Innovative Health, a medical device reprocessing company, sued J&J's Biosense Webster, alleging that certain business practices and contractual terms violated the antitrust laws by restricting competition in the sale of high density mapping catheters and ultrasound catheters.Innovative Health, medical device reprocessing company - home page: electrophysiology economics and the statement that some individual catheters cost more than $4,000. — 2026 · publ. 2026 · source ↗
- ReportedIn October 2019 Innovative Health, a medical device reprocessing company, sued J&J's Biosense Webster, alleging that certain business practices and contractual terms violated the antitrust laws by restricting competition in the sale of high density mapping catheters and ultrasound catheters.Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗
- ReportedIn May 2025 a jury returned its verdict in favour of Innovative Health, and in August 2025 the court issued a permanent injunction concerning Biosense Webster's business practices.Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗
- ReportedBiosense Webster appealed both.Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: consolidated sales, volume and price, geography, the three wholesalers, rebate accruals, costs, R&D and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
- ReportedElectrophysiology is the largest part of J&J's cardiovascular franchise, with $5,634 million of sales in 2025, and part of its strength is the link between the mapping system a hospital owns and the catheters it buys.Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: MedTech segment and franchise sales analysis. — FY2025 · publ. 11 February 2026 · source ↗
- ReportedInnovative Health's own case to hospitals is that electrophysiology economics are all about the cost per procedure of medical devices, and that some individual catheters cost more than $4,000.Innovative Health, medical device reprocessing company - home page: electrophysiology economics and the statement that some individual catheters cost more than $4,000. — 2026 · publ. 2026 · source ↗
- ReportedUnited States electrophysiology grew 5.8% in the second quarter of 2026 to $783 million.Johnson & Johnson second-quarter 2026 supplementary sales data, statement of earnings and non-GAAP reconciliation, Form 8-K exhibit 99.2 - MedTech segment and franchise sales by region. — Q2 2026 · publ. 15 July 2026 · source ↗
- ReportedActelion, a J&J subsidiary, faces a class action alleging it violated antitrust laws by refusing to supply generic manufacturers with samples of Tracleer, a pulmonary hypertension drug.Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗